Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781282 | 1.00 | MEN1 (0.37) | MEN1KMT2AGPR119NR1H2MAPK1 | |
| SCHEMBL17936828 | 0.77 | MAP4K4 (0.39) | MEN1KMT2AGPR119NR1H2MAPK1 | |
| SCHEMBL17926262 | 0.77 | MAP4K4 (0.39) | MEN1KMT2AGPR119NR1H2MAPK1 | |
| SCHEMBL17936822 | 0.77 | MAP4K4 (0.39) | MEN1KMT2AGPR119NR1H2MAPK1 | |
| SCHEMBL17936875 | 0.77 | RIPK1 (0.44) | GPR119NR1H2MAPK1POLB | |
| SCHEMBL31362299 | 0.77 | MEN1 (0.39) | MEN1KMT2AGPR119NR1H2PTPN1 | |
| SCHEMBL31362279 | 0.74 | MEN1 (0.34) | MEN1KMT2AGPR119NR1H2PTPN1 | |
| SCHEMBL31362437 | 0.74 | MEN1 (0.34) | MEN1KMT2AGPR119NR1H2PTPN1 | |
| SCHEMBL19780414 | 0.74 | ELANE (0.36) | MEN1KMT2AGPR119NR1H2PTPN1 | |
| SCHEMBL31362592 | 0.74 | GPR119 (0.40) | MEN1KMT2AGPR119NR1H2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181156-A1 | CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10562905-B2 | Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190322670-A1 | NOVEL CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018011160-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181156-A1 | CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | TPMT, CYP3A5, QDPR | MEN1 1974/4885KMT2A 4058/4885GPR119 950/4885 |
| US-10562905-B2 | Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseases | TPMT, CYP3A5, QDPR | MEN1 1974/4885KMT2A 4058/4885GPR119 950/4885 |
| US-20190322670-A1 | NOVEL CARBOXY TETRAHYDROPYRAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, GLS2, TPMT | MEN1 2797/4885KMT2A 4252/4885GPR119 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.